Custom Analysis

We allow users provide their customed parameters to the Markov models. performed based on the CLCG dataset. More importantly, our study made comprehensive efforts to cover all aspects of cancer treatment, from efficacy to overall costs for early-stage ENKTCL patients with an interdisciplinary approach.

The default country-specific threshold of Willingness to Pay was based on the estimates from Pichon-Riviere A, et al. Users can assess whether CMT is a cost-effective treatment in patients with early-stage ENKTCL from the country-specific payer's perspective. Additionally, users can modify the costs of RT and CT per cycle.

Interpretation of Results

All results were estimated from the CLCG dataset and aimed to estimate the cost effectiveness of front-line treatment with CMT compared to RT alone for patients with early-stage ENKTCL in different risk groups. Each patient is assigned a risk group based on the clinical characteristics of the disease, and the data is used to assess the health economic outcomes of combination chemotherapy, taking into account the patient's risk level and their willingness to pay.

Article

For the full article, visit the JCO Global Oncology.

Contact Us

Prof. Ye-Xiong Li, MD PhD.

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

No.17 Pan-jia-yuan South Lane, Chaoyang District, Beijing 100021, China.

E-mail: yexiong12@163.com

or

Dr. Jing Yang, MD PhD.

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

No.17 Pan-jia-yuan South Lane, Chaoyang District, Beijing 100021, China.

E-mail: yangjingdoctor@163.com